LUCD

Lucid Diagnostics Inc. (NASDAQ:LUCD) is a commercial-stage medical diagnostics technology company founded in 2018 and based in New York, New York. The company operates as a subsidiary of PAVmed Inc. and went public in October 2021. Lucid Diagnostics specializes in developing and commercializing diagnostic solutions for patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, particularly the highly lethal esophageal adenocarcinoma. The company has transitioned from early development to commercial operations, processing thousands of tests annually through its proprietary diagnostic platform.